Antioxidant weaknesses in KEAP1/NRF2-mutant non-small cell lung cancer
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
['FUNDING_OTHER'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11158716
This work aims to find drug targets that make non-small cell lung cancers with KEAP1 or NRF2 mutations more sensitive to chemotherapy and radiation.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11158716 on ClinicalTrials.gov |
What this research studies
If I have non-small cell lung cancer with KEAP1 or NRF2 mutations, this project looks for the cancer's antioxidant weak spots that cause treatment resistance. Researchers will study two main antioxidant systems (glutathione/GSR and thioredoxin/TXNRD) in lab-grown tumor cells and animal models to see which ones the tumor relies on. The team wants to identify targets that drugs could block so chemotherapy and radiation work better. Findings could point to new combination therapies for patients with these mutations.
Who could benefit from this research
Good fit: People with non-small cell lung cancer whose tumor genetic testing shows KEAP1 or NRF2 mutations, especially those facing chemo or radiation, are the most relevant candidates.
Not a fit: Patients without KEAP1 or NRF2 mutations or those with other lung cancer types (for example small cell lung cancer) are unlikely to benefit from the approaches studied here.
Why it matters
Potential benefit: If successful, this could produce treatments that make KEAP1/NRF2-mutant tumors more responsive to chemo and radiation, improving outcomes for those patients.
How similar studies have performed: Preclinical studies suggest targeting antioxidant pathways can sensitize tumors, but clinical success in patients is still limited and this approach remains largely at the preclinical stage.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIANG, CHANG — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: JIANG, CHANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cancers